1World Health Organization. Diabetes Mellitus. Facts sheet 2006, number 316. Available from: http://www.who.int/mediacentre/ factsheets/fs312/en/.
2Yang WY, Lu JM, Weng JP, et al. Prevalence of Diabetes among Men and Women in China[J]. N Eng 1J Med, 2010, 362(12): 1090-1101.
3The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus[J]. N Engl J Med, 1993,329(14): 977-986.
4UK Prospective Diabetes Study (UKPDS) Group. Intensive blood- glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)[J]. Lancet, 1998, 352(9131): 837-853.
5Home P. Contributions of basal and post-prandial hyperglycaemia to micro and macrovascular complications in people with type 2 diabetes [J]. Curr Med Res Opin, 2005, 21(7): 989-998.
6Leiter LA, Ceriello A, Davidson JA, et al. Post-prandial glucose regulation: new data and new implications[J]. Clin Ther, 2005, 27(Suppl 2): S42-S56.
7Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a con-sensus statement from the American diabetes Association and the European Association for theStudy of Diabetes [J]. Diabetes Care, 2006, 29(8): 1963-1972.
8Becker RH. Insulin glulisine complementing basal insulins: a review of structure and activity [J]. Diabetes Technol Ther, 2007, 9( 1):109-2 l.
9Heise T, Nosek L, Spitzer H, et al. Insulin glulisine: a faster onset of action compared with insulin lispro[J]. Diabetes Obes Metab, 2007, 9(5): 746-753.
10Amolds S, Rave K, Hovelmann U, et al. Insulin glulisine has a faster onset of action compared with insulin aspart in healthy volunteers [J]. Exp Clin Endocrinol Diabetes, 2010, 118(9): 662-664.
